Wikisage, the free encyclopedia of the second generation, is digital heritage
Brivaracetam: Difference between revisions
Jump to navigation
Jump to search
m (→Links) |
m (→Links: b) |
||
| Line 9: | Line 9: | ||
[http://www.epilepsybehavior.com/article/S1525-5050(15)00520-X/pdf An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam] | [http://www.epilepsybehavior.com/article/S1525-5050(15)00520-X/pdf An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam] | ||
{{Wikidata|Q408099}} | {{Wikidata|Q408099}} | ||
Revision as of 01:55, 30 March 2016
-
![(2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide](/w/images/thumb/6/64/Brivaracetam3d.png/120px-Brivaracetam3d.png)
(2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide
![(2S)-2-[(4R)-2-oxo- 4-propylpyrrolidin-1-yl] butanamide](/wiki/File:Brivaracetam3d.png)
4n propyl analog of levetiracetam, this and levetiracetam may have potential in the management of progressive myoclonic epilepsies [1][2]
Links
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm486827.htm
ATC